Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2025
Burden of community-acquired respiratory virus infections and impact on cancer treatment at a tertiary care cancer center in Japan.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujita Takahiro, Iida Takeharu
Аннотация
AIM: To clarify the burden of community-acquired respiratory virus (CRV) other than SARS-CoV-2 infections in adult patients with cancer and their impact on cancer treatment.
PATIENTS AND METHODS: We retrospectively examined positive cases using multiplex respiratory polymerase chain reaction panel tests at a Japanese tertiary-care cancer center. From April 2023 to March 2024, a total of 1629 tests were performed on 1068 patients.
RESULTS: CRV other than SARS-CoV-2 were identified in 128 cases. These include rhinovirus/enterovirus (47 cases), parainfluenza virus (22 cases), human coronavirus (18 cases), Respiratory syncytial virus (15 cases), influenza A (14 cases), and human metapneumovirus (10 cases). Pneumonia was observed in 19 (15.7 %) patients. In 38 patients (31.4 %), cancer treatment was postponed due to CRV other than SARS-CoV-2 infection.
CONCLUSION: CRV other than SARS-CoV-2infections contribute to delays in cancer treatment and are frequently associated with pneumonia. To ensure the safe continuation of cancer treatment, it is imperative to provide patients with appropriate infection control guidance and perform respiratory panel tests for an accurate diagnosis.
PATIENTS AND METHODS: We retrospectively examined positive cases using multiplex respiratory polymerase chain reaction panel tests at a Japanese tertiary-care cancer center. From April 2023 to March 2024, a total of 1629 tests were performed on 1068 patients.
RESULTS: CRV other than SARS-CoV-2 were identified in 128 cases. These include rhinovirus/enterovirus (47 cases), parainfluenza virus (22 cases), human coronavirus (18 cases), Respiratory syncytial virus (15 cases), influenza A (14 cases), and human metapneumovirus (10 cases). Pneumonia was observed in 19 (15.7 %) patients. In 38 patients (31.4 %), cancer treatment was postponed due to CRV other than SARS-CoV-2 infection.
CONCLUSION: CRV other than SARS-CoV-2infections contribute to delays in cancer treatment and are frequently associated with pneumonia. To ensure the safe continuation of cancer treatment, it is imperative to provide patients with appropriate infection control guidance and perform respiratory panel tests for an accurate diagnosis.